title: Thallium-201 imaging in the assessment of tumor response to anti-tumor treatments.
abstract: The advantages and limitations of (201)Tl imaging in assessing the tumor response to anti-cancer therapy are discussed in this review. (201)Tl has distinctive advantages but more recent agents such as (99m)Tc MIBI and positron emitters have some clinical superiorities over (201)Tl in this usage.
authors.affiliation: Department of Nuclear Medicine, Kocaeli University, School of Medicine, Kocaeli, Turkey.
authors.forename: F
authors.initials: F
authors.lastname: Berk
authors.forename: H
authors.initials: H
authors.lastname: Demir
authors.forename: C
authors.initials: C
authors.lastname: Aktolun
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy; D006258:Head and Neck Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy; D009369:Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D011379:Prognosis; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D012983:Soft Tissue Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy; D013793:Thallium; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D019275:Radiopharmaceuticals; C027549:thallium chloride; D013793:Thallium